Semaglutide or Tirzepatide Added to Psychological Support in Binge Eating Disorder With Overweight or Obesity: The LEAP ‐ BED Prospective Pilot Study
Diabetes Obesity and Metabolism · 2026
Abstract e pubblicazione originale
L’abstract è consultabile nella fonte originale. Non viene ripubblicato qui perché non risulta verificata una licenza compatibile.
Leggi nella fonte originale ↗Parole chiave
Weight lossEating BehaviourGlp‐1 Receptor AgonistAnti‐Obesity MedicationsIncretin‐based TherapyDual Gip/glp‐1 Receptor AgonistGLP‐1 receptor agonistanti‐obesity medicationsdual GIP/GLP‐1 receptor agonisteating behaviourincretin‐based therapyweight lossbinge eating disorderobesitysemaglutidetirzepatideanti-obesity drugspsychological supportGLP-1 receptor agonistsGIP/GLP-1 receptor agonistBinge Eating Scaleinsulin resistanceanthropometric outcomesmetabolic outcomesEating Disorders and BehaviorsPharmacology and Obesity TreatmentObesity, Physical Activity, Diet
Come citare questo studio
Maria Elena Spoltore, Davide Masi, Chandra Massetti, Krzysztof Glaser, Marta Moretti, Antonio Angeloni, Daniele Gianfrilli, Mikiko Watanabe. (2026). Semaglutide or Tirzepatide Added to Psychological Support in Binge Eating Disorder With Overweight or Obesity: The LEAP ‐ BED Prospective Pilot Study. Diabetes Obesity and Metabolism. DOI: 10.1111/dom.71510
Consulta la pubblicazione originale ↗